Bronchiectasis is characterised by pathological dilation of the airways. More specifically, the radiographic demonstration of airway enlargement is the common feature of a heterogeneous set of conditions and clinical presentations. No approved therapies exist for the condition other than for bronchiectasis caused by cystic fibrosis. The heterogeneity of bronchiectasis is a major challenge in clinical practice and the main reason for difficulty in achieving endpoints in clinical trials. Recent observations of the past 2 years have improved the understanding of physicians regarding bronchiectasis, and have indicated that it might be more effective to classify patients in a different way. Patients could be categorised according to a heterogeneous group of endotypes (defined by a distinct functional or pathobiological mechanism) or by clinical phenotypes (defined by relevant and common features of the disease). In doing so, more specific therapies needed to effectively treat patients might finally be developed. Here, we describe some of the recent advances in endotyping, genetics, and disease heterogeneity of bronchiectasis including observations related to the microbiome.
Introduction
Bronchiectasis is defined as permanent enlargement of the airways, 1 and is mostly the result of an intrinsic airway pathology resulting in dilation. Multiple causes of bronchiectasis and a broad array of clinical presentations exist. 2 The extent of bronchiectasis can range from focal disease (limited to one segment or lobe) to diffuse disease (involving both lungs and all lobes). Bronchiectatic findings range from subtle dilation to cystic changes in the airways. Some patients will be asymptomatic and the bronchiectasis is dis covered unexpectedly, whereas others will have daily symptoms of cough and sputum production with periodic exacerbations. 3 The diagnosis of bronchiectasis is increasing worldwide. Previously classified as a rare or orphan disease, bronchiectasis has now been reported at rates of up to 566 per 100 000 population with an incidence that has increased by 40% in the past 10 years. 4 Despite having its own diagnostic code, there are no medi cations or therapies approved by regulatory authorities in the USA or Europe for most cases of bronchiectasis. The exception is bronchiectasis due to cystic fibrosis, for which several approved medications exist, but none are approved as treatments for bronchi ectasis of other causes. 5 However, guidelines that recommend treatments for bronchiectasis are available, 5 and reports have shown that some therapies are associated with clinical benefit, 6 ,7 suggesting that we need to improve our ability to identify those patients with bronchiectasis. 8, 9 The pathway to more precise treatment will require a better understanding of patients beyond imaging studies. Here, we review recent studies, particularly focusing on the past 2 years, that have attempted to better describe patients according to a heterogeneous group of endotypes (defined by a distinct functional or pathobiological mechanism 10 ) or clinical phenotypes (defined by relevant and common features of the disease 11 ).
Pathophysiology of disease
The list of conditions known to cause or be associated with bronchiectasis is long, but most have common features that lead to the remodelling and dilation of the airways. A useful pathophysiological pathway has described the process as a cycle of events promoting impaired mucociliary clearance and retention of airway secretions. These events disrupt the host's defences and render the airways more susceptible to establishment of chronic infection. The persistence of bacterial pathogens incites an inflammatory response that results in injury and pathological remodelling of the airways leading to bronchiectasis. Each step begets the next, resulting in a persistent and progressive process over time. This model has worked well to describe how numerous conditions enter into the cycle: patients with cystic fibrosis and primary ciliary dyskinesia have impaired mucociliary clearance; immune deficiency can result in
Search strategy and selection criteria
We searched PubMed using the search terms "bronchiectasis", "endotype", "genotype", "microbiome", and "heterogeneity". We focused on papers and reviews published from Jan 1, 2010 to March 1, 2018 in English. We also searched author names of key people in the bronchiectasis field. From key papers, we reviewed reference lists to find additional pertinent papers and to redefine search terms. For the concept of endotyping, we searched this term in combination with other major pulmonary diseases (eg, asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis) to look for similar categorisations.
recurrent and persistent infection; injury to the airways, either because of severe infection or mechanical injury (eg, toxic inhalation or chronic aspiration) can result in an impaired healing of the airways, and so on. However, interactions are far more complex with each pathophysiological step contributing to all others. This process can be better described as a vortex (figure 1). The vortex concept might better explain why individual treatments (eg, antibiotics or antiinflammatories) in isolation have only modest effects on clinical outcomes in bronchiectasis. Rather than breaking a vicious cycle, which would be expected to halt disease, antibiotics, for example, only affect one component of the vortex suggesting that inflammation and lung damage can be sustained by other stimuli. This model argues for multimodal treatment that addresses all aspects of the disease. How this pathophysiological model results in dilation of the airways and why such heterogeneity in the extent of the disease exists are less well understood. A simple explanation is that impaired mucociliary function results in an accumulation of material that obstructs and stents the airway (material collects in the airways and exerts an outward pressure on the wall) while remodelling occurs. Another hypothesis can be found in the study of polycystic kidney disease in which a non motile ciliary abnormality in renal epithelial cells results in cellular hypertrophy and hyperplasia, and cyst formation.
12 Because some patients with polycystic kidney disease also have bronchiectasis, 13 this cooccurrence suggests there could be a link between cilia, cellular signalling processes, and bronchiectasis. An animal ciliary knockout model of polycystic kidney disease showed loss of airway motile cilia and bronchial remodelling in the absence of inflammation, but with proliferation of facultative progenitor cells.
14 Such a role for ciliary function might offer a commonality among the varied causes of bronchiectasis.
The radiographic features help to explain why some patients will have focal disease (eg, because of severe injury) rather than diffuse (eg, primary ciliary dyskinesia), or why some have disease in the lower lobes (eg, recurrent aspiration). Although some diagnoses have easily available and interpretable diagnostic testing (such as cystic fibrosis), others are less easily established. This diagnosis still might not be sufficient in defining which patients are likely to respond to specific therapies. Alternative characteristics (eg, genotyping or biomarkers) might better characterise patients to understand how best to develop and use therapies.
Endotypes and genotypes
Although most patients will be diagnosed with idio pathic bronchiectasis, indicating that the cause could not be found following testing, reviewing conditions with well known, geneticsbased pathways offers insights into understanding the underlying mecha nisms of bronchiectasis pathogenesis. These insights can aid in the development of specific treatment regimens. However, the interactions between genetics, endotypes, environ ment, and therapeutic interventions can vary. In asthma, for example, studies focused on genetic risk loci have not yielded a clear pathway to therapeutic intervention, whereas classification based on in flammatory endo types can correlate with effective, specific antiinflammatory therapies.
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Cystic fibrosis
Cystic fibrosis serves as the prime example of how disease categorisation based on genotype can drive effective therapeutic intervention. Cystic fibrosis is primarily a disorder of mucociliary clearance caused by altered epithelial ion transport. Well characterised biomarkers exist, such as sweat chloride and trans epithelial potential difference assays, which have been useful in the diagnosis and research assessment of therapeutic response. 16 Discovery of the causative gene for cystic fibrosis in 1989 led to increasing knowledge of the protein product, cystic fibrosis transmembrane conductance regulator (CFTR). This included its structure, function, and the protein synthesis pathway from nucleus to insertion, and proper functioning in the epithelial apical membrane. 17, 18 The correlation between specific genetic mutations and their effect on CFTR quantity and function has led to remarkable genotypespecific treatment that can sub stantially im prove the clinical course of bronchiectasis and other manifestations of disease (figure 2). Although airway dilation can remain, airway inflammation, se cretion clearance, and control of infection can all improve with CFTR modulator therapy.
20,21
Primary ciliary dyskinesia
Primary ciliary dyskinesia is another genetic disorder of mucociliary clearance characterised by disordered function of motile cilia. Bedside measurement of nitric oxide production is a useful biomarker of ciliary motility, 22 but it must be emphasised that primary ciliary dyskinesia genotypes associated with normal concentrations of nasal nitric oxide have been described. 23 Measurement of nasal nitric oxide production and highspeed video assessment of ciliary beat characteristics might be useful markers of drug efficacy in future clinical trials. 24 In contrast to the monogenic cause of cystic fibrosis, the assembly and regulation of ciliary proteins is under the control of multiple genes. 25 Although electron micro scopic exami nation of crosssectional cilia anatomy lacks sufficient sensitivity and specificity to be a useful diagnostic test, correlation has been noted in research settings between mutated genes and structural abnormalities (figure 3). As drug development for primary ciliary dyskinesia advances, this relationship of genotypefunction or structure function might prove useful for drug targeting similar to the path that CFTR modulator therapeutics development has taken in cystic fibrosis.
Immune deficiencies
Bronchiectasis is a common manifestation of many primary immune deficiencies and disorders of immune regulation. These conditions can be subdivided roughly on the basis of the primary immune cells of origin. Biomarkers that can be useful in diagnosis and assess ment of treatment include lymphocyte phenotyping with delineation of T cell, B cell, and natural killer cell numbers, quantitative immunoglobulin concentrations, and specific antibody responses to protein and poly saccharide antigens. Humoral immune deficiencies account for approximately 70% of all primary immune deficiencies and the majority of primary immune deficiencyassociated causes of bronchiectasis. 27 Although abnormally low immunoglobulin concentrations could point toward this subgroup, knowledge of the underlying genetic causes are of increasing importance for directing specific therapies or for early identification of patients who would benefit from bone marrow transplantation. Common variable immune deficiency, the most Figure 2: CFTR mutation classification CFTR mutation classification based on molecular defect. These molecular defects correspond to therapeutic approaches to restore the quantity of protein or its function, or both resulting in genotype specific CFTR modulator drugs used alone (ivacaftor) or in combination (lumacaftor-ivacaftor, tezacaftor-ivacaftor).
Reproduced from Lopes-Pacheco. 19 CFTR=cystic fibrosis transmembrane conductance regulators. Cl=chloride ion. 28 Xlinked agam m aglobulinaemia is caused by mutations in the Bruton's tyrosine kinase gene and can result in a profound humoral immune deficiency. 29 However, even Xlinked agammaglobulinaemia can have a variable clinical phenotype on the basis of genotype, with adults having a higher proportion of splicesite mutations and lower proportion of frameshift mutations than children. 30 The autosomal dominant hyperimmunoglobulin E syndrome (Job's syndrome) is another example of a rare primary immune deficiency that can be identified by its characteristic of markedly elevated IgE concentrations and clinical findings of eczema, recurrent skin and pulmonary infections, skeletal abnormalities, and coarse facial features. However, with this disease, the high IgE concentration is more of a disease marker than a path way indicator. This disease has been better defined by identification of mutations in the signal transduction and activator of transcription 3 (STAT3) gene. 31 STAT3 is important for several key airway defence mechanisms including T helper 17based cytokine signalling leading to up regulation of antimicrobial peptides. It is also considered to have a role in proper remodelling after epithelial injury by directing differentiation of airway basal cells into ciliated cells and away from mucus secreting epithelial cells. 32 Mutations in STAT3 affecting these pathways are likely to account for the high prevalence of bronchiectasis and cystic changes (pneuma to celes) seen in this disease. With the availability of whole exome sequencing, it is probable that mutations in genes affecting immune function and regulation will be identified. These mutations could account for unsus pected underlying systemic immune causes for patients with recurring respiratory tract infections leading to bronchiectasis with atypical late presentations diagnosed in adulthood. 33, 34 Autoimmune diseases Several autoimmune diseases, most notably rheumatoid arthritis and inflammatory bowel disease, are associated with bronchiectasis. These conditions typically have predominant manifestations outside of the respiratory tract. Biomarkers such as rheumatoid factor, Creactive protein, antinuclear cytoplasmic antibodies, and anti Saccharomyces cerevisiae antibodies might be helpful in identifying these diseases in patients presenting with joint or bowel symptoms; however, they are not so helpful in characterising the associated airway disease. Although infections might be common in bronchiec tasis associated with these disorders, the inflammatory component frequently predominates. In the case of ulcerative colitisassociated bronchiectasis, the airway findings of cobblestoning, ulcerations, and mucosal lympho plasmo cytic infiltration can mimic bowel findings. These pulmonary manifestations can respond to antiinflam matory agents such as inhaled or systemic steroids; however, some cases might require tumour necrosis factor α blockade (once infection is identified and controlled with antibiotics) or other immuno modulatory drugs commonly used to treat bowel inflam mation to control the progression of bronchiectasis. 35 Causative genes have not been identified for rheumatoid arthritis and inflammatory bowel disease (ulcerative colitis). However, for inflammatory bowel disease, 
Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis represents a unique overlap between immune dysregulation and obstructive airway diseases such as asthma and cystic fibrosis. Although allergic bronchopulmonary asper gillosis is associated with filamentous fungi in the airway, biomarkers of the allergic inflammatory response (eg, eosinophilia, total IgE, serum precipitins, and Aspergillus specific IgE with IgG as a marker of Aspergillus fumigatus exposure) are prominent in the diagnostic criteria. 37, 38 The bronchiectasis is frequently proximal and might have an exaggerated saccular, plugged appearance. A 2016 study, comparing patients with allergic broncho pulmonary aspergillosis with those who have atopic asthma and healthy participants, identified allergic bronchopulmonary aspergillosisassociated single nucleo tide polymorphisms in TLR3, IL4R, and IL13. 39 These polymorphisms and other reported potential genetic susceptibility loci could be helpful in elucidating pathways and pointing to more specific therapies.
Chronic obstructive pulmonary disease (COPD) and asthma
The general relationship between asthma, COPD, and bronchiectasis remains unclear as to directionality of development. 40 Bronchiectasis can be present in both asthma and COPD and has been associated with more advanced stages of these diseases. 41, 42 Conversely as bronchiectasis progresses, increasing degrees of chronic airway obstruction can be seen and labelled as COPD and some patients with bronchiectasis could have eosinophilia, elevated IgE, and at least partly reversible airway obstruction suggesting an asthmatic component to their disease. Bronchiectasis has been historically underrecognised; therefore, some of the overlap represents historical misdiagnosis. Endotyping to guide therapy has garnered much attention in asthma management and biomarkers (eg, eosinophilia or increased IgE) could be useful in identifying patients with bronchiectasis who might benefit from directed antiinflammatory treatment. The prime example of genetic overlap between COPD and bronchiectasis is α1antitrypsin deficiency in which a correlation exists between the amount of the biomarker, the genotype, and disease severity.
Idiopathic bronchiectasis associated with non-tuberculous mycobacteria (NTM)
Since the late 1980s, there has been increasing recognition of a population of patients with idiopathic bronchiectasis, many of whom are chronically infected with NTM. 43 This group of patients are reported predominantly as women who are postmenopausal and nonsmokers with no known predisposing factors who present with chronic cough. 44 They share characteristics with other endotypes, notably a high prevalence of CFTR mutations and evidence of ciliary dysfunction, 24, 45, 46 but they do not meet diagnostic criteria for cystic fibrosis or primary ciliary dyskinesia. Such observations suggest the cause of the condition is likely to be multifactorial in which mucociliary clearance defects could play a key role.
These patients have physical characteristics such as a tall, asthenic morphotype, scoliosis, pectus excavatum, mitral valve prolapse, and dural ectasia, which overlap with heritable connective tissue disorders such as Marfan syndrome and EhlersDanlos syndrome. 46, 47 Both bronchiectasis and pulmonary NTM infections have been noted in a well characterised population with these heritable connective tissue disorders. 48 Conversely, key characteristics such as bronchiectasis, NTM infection, and connective tissue disease features have been reported in a high proportion of first and second degree relatives of carefully phenotyped patients with idiopathic bronchiectasis and pulmonary NTM infections, strongly suggesting a genetic component to the disease. 48 Whole exome sequencing, with use of a candidate gene analysis of low frequency, potentially proteinaltering variants, identified a statistically significantly higher prevalence of variants in connective tissue diseaseassociated genes and in mucociliary clearanceassociated (CFTR and ciliarelated) genes in probands affected by NTM and family members affected and unaffected by NTM 
Cilia variants Motility enhancer: 24 Sildenafil
Cystic fibrosis variants CFTR modulator: 51 
Ivacaftor, Lumacaftor
Connective tissue variants TGF-β attenuator: 52 Losartan
Immune variants
Immune modulator: 50 
GMCSF
Idiopathic bronchiectasis or pulmonary non-tuberculous mycobacteria compared with a healthy control reference population. 49 Many of the family members unaffected by NTM had bronchiectasis or connective tissue disease traits, or both. A higher prevalence of variants in genes related to systemic mycobacterial control distinguished family members with pulmonary NTM from those without NTM. Using a combination of phenotypic character istics (tall, asthenic morphotype, and dural ectasia), biomarkers (sweat chloride, nasal nitric oxide, and ciliary beat frequency), and genetic analysis, it might be possible to place patients with idiopathic bronchiectasis into key endotypes that could eventually point to a role for directed therapeutic interventions to address the underlying predisposing factors for disease development and progression. Theoretically, drugs which modulate CFTR function, modulate ciliary beating characteristics, mitigate vascular and other sequelae of connective tissue disorders, or enhance relevant systemic immune pathways could alter host susceptibility and improve the disease course in patients with idiopathic bronchiectasis and chronic NTM infections (figure 4).
Disease heterogeneity beyond causes: clinical phenotypes
Assessing patients with bronchiectasis requires knowledge of the heterogeneity of clinical presentation and variable clinical course. Patients with apparently mild symptoms at presentation could still have adverse prognostic factors and have rapid progression of disease, whereas others with seemingly severe symptoms at the outset might be easily managed and have a good prognosis. 53 A multidimensional approach to patient Note that patients do not always present with classic features and therefore the absence of these signs cannot be used to exclude a specific cause in bronchiectasis. Consensus guidelines recommend standard testing irrespective of clinical phenotype. [57] [58] [59] However, many of these features remain nonspecific and so efforts have been made to identify clinically recognisable sets of observable characteristics that link to clinical outcomes (ie, clinical phenotypes). 60 Exacerbations of bronchiectasis, defined clinically as worsening of the usual respiratory symptoms, 61 are important events in the natural history of bronchiectasis. Patients with three or more exacerbations a year had worse health status, were more likely to be hospitalised for treatment, and had increased mortality. 62 Most importantly, frequent exacerbation was identified as a true phenotypic trait because the majority of patients consistently had these exacerbations over time, whereas patients who did not have a history of exacerbations rarely had events during followup. As shown for COPD 63 and cystic fibrosis, 64 a history of exacerbations in patients with bronchiectasis is the strongest predictor of future events, whereas individual comorbidities, bacteriology, severity of disease determined radiographically, and other variables explained only a very small amount of the variance in exacerbation frequency. 62 This finding suggests that what leads a patient to have frequent exacerbations is not fully understood. Therefore, in clinical practice, a history of exacerbations is the only variable that can be confidently used for prediction of future events.
Various studies have attempted to use statistical clustering techniques to identify subgroups of patients with bronchiectasis with different characteristics. 65, 66 Most identified clusters have been based on current age, age of onset of disease, and disease severity, and none have been replicated in independent cohorts suggesting that they are not true phenotypes. The major phenotype identified in all cohorts of patients with bronchiectasis is chronic infection with Pseudomonas aeruginosa. Patients with chronic infection due to P aeruginosa have an increased burden of disease including a higher frequency of exacerbations, worse healthrelated quality of life, increased risk of hospital admissions, and increased mortality. [67] [68] [69] P aeruginosa can exhibit adaptive behaviours allowing it to survive in a hostile environment such as the human airways, and the production of biofilms obstructs exposure of the bacteria to antibiotics and phagocytes. 70, 71 P aeruginosa also produces virulence factors that allow it to evade phagocyte killing and slow ciliary beat frequency, further allowing it to maintain its presence. 72 The mere presence of P aeruginosa has not been sufficient to define patients who benefit from aerosolised supp ressive antibiotic therapy; 8 however, because there are patients who do benefit from inhaled antibiotics, 6 this suggests there could be other factors (eg, bacterial abundance) that are more predictive.
Patients who have socalled dry bronchiectasis do not produce daily sputum, a syndrome that has been long recognised. A case series published in 1933 describes 20 cases arising from infections in childhood in whom bronchiectasis was associated with cough and occasional haemoptysis without prominent sputum production. 73 Such patients have lower symptom scores but surprisingly have a higher mortality than patients who have chronic infection or daily sputum. 65 Dry bronchiectasis has been traditionally associated with NTM infection.
By contrast, a group of patients have been observed who present with excessive sputum production but without the consistent finding of bacteria in sputum cultures. Such patients are described as having sterile bronchorrhea although modern molecular microbiology techniques teach us that sputum samples are never sterile. 74 This group has been typically associated with inflammatory bowel disease, in whom sputum samples contain neutrophils and necrotic material but do not have detectable pathogens. 75 Further research is required to identify other meaningful clinical phenotypes that are independent of cause.
Microbiology and the microbiome
Chronic bacterial infection is a characteristic in many patients with bronchiectasis. The term chronic infection is preferred to colonisation because colonisation implies a benign process whereas chronic infection is more reflective of the longterm interaction between micro organisms and the host leading to progressive tissue damage. Sputum culture remains an important part of management because the presence of some organisms has prognostic implications. This information can help guide treatment of exacerbations and could identify patients for whom longterm suppressive antibiotic therapy might be effective. 76 Traditional culture methods for bacteria show that nearly 80% of patients will regularly grow pathogens in sputum samples, the most frequent being P aeruginosa and Haemophilus influenzae, but other Gramnegative (eg, Moraxella catarrhalis, Escherichia species, and Klebsiella species) and Gram positive (eg, Streptococcus pneumoniae and Staphylococcus aureus) bacteria are isolated frequently. 77 Although H influenzae and P aeruginosa are the most common organisms identified in European studies, the US bronchiectasis registry reported high proportions of isolation of NTM (50%) and P aeruginosa (33%), whereas H influenzae was relatively uncommon (8%). 78 The reason for the higher frequency of NTM in the USA is not clear, but might reflect some element of selection bias as many US registry sites are also referral centres for NTM lung disease. 78 The understanding of chronic infection in bronchi ectasis is evolving with the advent of sequencing technologies that allow a more comprehensive profiling of the bacterial communities in the lung, termed the microbiome. A microbiome analysis of healthy airways reveals a rich, diverse community of bacteria that are present in low abundance. 79 It is premature to define the flora of the airways as healthy, as some, or all, of these microorganisms could represent transient populations introduced through microaspiration. Across many respiratory diseases it has been shown that disease is associated with a loss of bacterial diversity, (ie, through the loss of important bacterial taxa), or by the dominance of a single taxon or small group of taxa. 80 The dominance of a single taxon or small group of taxa is referred to as a loss of evenness of the microbiota, whereas the loss of diversity is referred to as a loss of richness. Measures of richness and evenness, or composite diversity measures such as the ShannonWiener diversity index have a positive linear correlation with lung function in bronchiec tasis, 81 although it cannot be stated whether this result is causal or due to frequent antibiotic exposure as studies to date have been mostly crosssectional. The proteobacteria, which include Pseudomonas and Haemophilus, come to dominate the diseased dysbiotic airway in bronchiectasis 82 and have been associated with more neutrophilmediated inflammation and exacer bations. 80 However, there is a subgroup of patients with microbiota dominated with firmicutes (eg, the anaerobe Veillonella) that have frequent exacerbations despite lower amounts of neutrophilic inflammation. [83] [84] [85] There is still much to learn about microbiota changes relevant to the development of bronchiectasis and its progression. The importance of early persistent bacterial infection in cystic fibrosis and primary ciliary dyskin esia is well established; interest is growing in persistent bacterial bronchitis in children, which could lead to development of bronchiectasis, suggesting that aggressive treatment with antibiotics could ultimately prevent this development from happening. 86 The same or similar phenomenon almost certainly exists in adults. 87 Changes in the microbiome could also contribute to exacerbations; changes occur in the microbiome as a consequence of antibiotic exposure, and after removal of the antibiotic exposure the microbiome can return to its previous state or remain altered (for better or for worse). Additionally, there might be interactions between species that could influence their virulence and pathogenicity. 88 Study results of microbiome changes have been inconsistent and could be more related to the individuals studied or to the differences in the treatments used. Indeed, one study found very little change in composition of the microbiome over time despite antibiotic treatment and exacerbations. 82 A longterm study of macrolide antibiotics (the BLESS study) showed a decreased overall diversity of the microbiome and increase in the relative abundance of Pseudomonas as a result of the reduced relative abundance of other organisms sensitive to macrolides. 89 The clinical relevance of this observation is not known, but was not associated with an increase in clinically relevant P aeruginosa infections. However, the findings suggest that antibiotic treatment could contribute to potentially pathogenic changes in the microbiota in some cases. Although bacteria have received the most attention in microbiome studies, fungi and mycobacteria are also important in bronchiectasis. A fumigatus has been isolated in patients with advanced disease and in individuals with allergic bronchopulmonary aspergillosis. Aspergillus is the taxa that most greatly differs between healthy individuals and patients with bronchiectasis and its abundance has been associated with exacerbations, suggesting that Aspergillus could be an important contributor to airway inflammation in some patients. 90 By contrast, Candida albicans has less clinical significance. It is also frequently isolated, and although some studies suggest a higher frequency of exacerbations in patients with Candida in sputum cultures, this finding could reflect reverse causation as Candida might be isolated after antibacterial treatment as a result of disturbance of bacterial microbiota.
Most studies to date are inherently limited by the biases of research methods in that these microbiota studies do not adequately detect mycobacteria, 91 do not detect fungi or viruses, and underestimate amounts of some typical bacteria such as Staphylococcus. Emerging approaches such as metagenomics allow comprehensive detection of bacterial, viral, and fungal populations simultaneously, while also potentially providing data for the carriage of virulence genes and genes associated with antimicrobial resistance. 92 Cost, technical, and bioinformatics limitations are gradually being overcome to allow these studies to be done more widely.
Conclusion
Ultimately, clinical variables can only provide modest predictive accuracy for bronchiectasis outcomes and provide little information about the underlying biology of the disease. Recent progress in understanding genotypes and endotypes, the process of defining groups of patients by pathobiology often with use of biomarkers, is at an early stage in bronchiectasis but offers promising approaches to develop therapeutic interventions for some patients with bronchiectasis. Hopefully, in the near future a standardised approach to the evaluation of patients with bronchiectasis will exist, and will use genetic analyses and local and systemic biomarkers to stratify patients in terms of prognosis and therapy.
